MindMed has dosed the first subject in a Phase III study of MM120 tablets for the treatment of generalised anxiety disorder.

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...

For the first time ever, researchers are administering LSD to patients in a Phase 3 clinical trial. The new study focuses on whether the psychedelic can be used to effectively treat generalized ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...